Repligen Corporation to Present at William Blair Growth Conference
Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing technology company, has announced its participation in the William Blair 45th Annual Growth Stock Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing technology company, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The event is scheduled for June 3-5 in Chicago. Olivier Loeillot, President and CEO, will deliver a company overview presentation on June 3rd at 1:20 p.m. CT. Investors can access the live webcast through Repligen's Investor Relations website, with a replay available for a limited time after the event.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was +0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT.
A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.